
David Ricks said he was doubtful whether tariffs would succeed in bringing jobs and money to the US The boss of US pharmaceutical giant Eli Lilly has told the BBC there is no looking back from Donald Trump's decision to impose sweeping tariffs on imports from the rest of the world. In an exclusive interview, David Ricks described it as a watershed moment in US economic history, "I think it's a pivot in US policy and it feels like it'll be hard to come back from here.
Main Idea: Eli Lilly boss David Ricks says Trump’s new tariffs mark a turning point in US policy and could hurt drug research and investment.
Key Points:
Tariffs could raise costs for medicines and force Eli Lilly and other firms to cut jobs or research, which may slow new treatments for patients.
Some drug and factory work could move back to the US, which may help certain workers and local communities.
Rate how each entity in this article affected the American people.
Eli Lilly chief executive and the named source of the article’s central comments on tariffs, investment, and R&D.
The pharmaceutical company at the center of the story, discussed for its investments, manufacturing, and exposure to tariffs.
His tariff decision is the main policy action being evaluated by the article and by David Ricks.
Discussed as a country whose life sciences position and regulation are being criticized by Ricks.
Named UK minister whom Ricks says he spoke to about the issues raised.
Cited as a comparison point for medicine spending in Ricks’s comments.
Named UK minister whom Ricks says he spoke to about the issues raised.
Comments here are the same thread shown when this article appears in The Pulse.
No comments on this article yet.
Sign in to commentOne of the senior UK officials Ricks says he briefed on his concerns.